# High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

> **NCT00417690** · PHASE2 · TERMINATED · sponsor: **Jacobus Pharmaceutical** · enrollment: 54 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** 4-Aminosalicylic acid
- **DRUG:** PASER placebo granules

## Key facts

- **NCT ID:** NCT00417690
- **Lead sponsor:** Jacobus Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2007-12
- **Final completion:** 2008-10
- **Target enrollment:** 54 (ESTIMATED)
- **Why stopped:** Efforts at recruitment have halted as recruitment was poor.
- **Last updated:** 2008-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417690, "High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00417690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*